Combination of ibrutinib and chemotherapy produced a durable remission in multiply relapsed diffuse large B-cell lymphoma leg type with mutant MYD88 and wildtype CD79
2017
The mutant Myd88L265P protein promotes lymphoma cell survival in diffuse large B-cell lymphoma (DLBCL) by activating NF-κB via Irak-4. On the other hand, constitutively activated signaling of the B-cell receptor (BCR), encoded by CD79A/B , activates NF-κB via Bruton’s tyrosine kinase (Btk).
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
9
References
7
Citations
NaN
KQI